AKT2 and glioblastoma: When combined with gamitrinib (a mitochondrial homeostasis inhibitor), PI3Ki effectively eliminated PI3K/Akt2/CypD pathway-mediated tumor resistance and significantly induced glioblastoma cell apoptosis.